» Articles » PMID: 15140992

Mutational Analyses of Epstein-Barr Virus Glycoprotein 42 Reveal Functional Domains Not Involved in Receptor Binding but Required for Membrane Fusion

Overview
Journal J Virol
Date 2004 May 14
PMID 15140992
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Epstein-Barr virus (EBV) is a human gammaherpesvirus associated with malignancies of both epithelial and lymphoid origin. Efficient infection of the latent host reservoir B lymphocytes involves the binding of glycoproteins gp350/220 for initial attachment, followed by the concerted action of gH, gL, gB, and gp42 for membrane fusion. The type II membrane protein gp42 is required for infection of B cells and assembles into a complex with gH and gL. The cellular host receptor for gp42, class II human leukocyte antigen (HLA), has been structurally verified by crystallization analyses of gp42 bound to HLA-DR1. Interestingly, the crystal structure revealed a hydrophobic pocket consisting of many aromatic and aliphatic residues from the predicted C-type lectin domain of gp42 that in other members of the C-type lectin family binds major histocompatibility complex class I or other diverse ligands. Although the hydrophobic pocket does not bind HLA class II, mutational analyses presented here indicate that this domain is essential for EBV-induced membrane fusion. In addition, mutational analysis of the region of gp42 contacting HLA class II in the gp42-HLA-DR1 cocrystal confirms that this region interacts with HLA class II and that this interaction is also important for EBV-induced membrane fusion.

Citing Articles

Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection.

Zhao G, Fang X, Bu G, Chen S, Sun C, Li T Cell Rep Med. 2024; 5(5):101573.

PMID: 38776874 PMC: 11148859. DOI: 10.1016/j.xcrm.2024.101573.


Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.

Bu W, Kumar A, Board N, Kim J, Dowdell K, Zhang S Immunity. 2024; 57(3):559-573.e6.

PMID: 38479361 PMC: 11000673. DOI: 10.1016/j.immuni.2024.02.008.


Neutralizing antibodies against EBV gp42 show potent protection and define novel epitopes.

Wu Q, Zhong L, Wei D, Zhang W, Hong J, Kang Y Emerg Microbes Infect. 2023; 12(2):2245920.

PMID: 37542379 PMC: 10443957. DOI: 10.1080/22221751.2023.2245920.


The structural basis of herpesvirus entry.

Connolly S, Jardetzky T, Longnecker R Nat Rev Microbiol. 2020; 19(2):110-121.

PMID: 33087881 PMC: 8579738. DOI: 10.1038/s41579-020-00448-w.


Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.

Bu W, Joyce M, Nguyen H, Banh D, Aguilar F, Tariq Z Immunity. 2019; 50(5):1305-1316.e6.

PMID: 30979688 PMC: 6660903. DOI: 10.1016/j.immuni.2019.03.010.


References
1.
Heineman T, Gong M, Sample J, Kieff E . Identification of the Epstein-Barr virus gp85 gene. J Virol. 1988; 62(4):1101-7. PMC: 253115. DOI: 10.1128/JVI.62.4.1101-1107.1988. View

2.
Yaswen L, Stephens E, Davenport L, Hutt-Fletcher L . Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein. Virology. 1993; 195(2):387-96. DOI: 10.1006/viro.1993.1388. View

3.
Spriggs M, Armitage R, Comeau M, Strockbine L, Farrah T, MacDuff B . The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol. 1996; 70(8):5557-63. PMC: 190515. DOI: 10.1128/JVI.70.8.5557-5563.1996. View

4.
Epstein M, ACHONG B, BARR Y . VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet. 1964; 1(7335):702-3. DOI: 10.1016/s0140-6736(64)91524-7. View

5.
Tanner J, Weis J, Fearon D, Whang Y, Kieff E . Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987; 50(2):203-13. DOI: 10.1016/0092-8674(87)90216-9. View